Breakthroughs for anxiety and depression, backed by research.

We report our outcomes so Mindbloom® clients can begin their journey with trust and confidence.

Achieve meaningful improvement in depression and anxiety symptoms.

Mindbloom’s ketamine treatment helps to transform lives. Our outcomes show it’s effective.

Clients with moderate or severe depression who report improvement in symptoms after two sessions (1+ points on PHQ-9 )

of clients report improvement in depression symptoms  ¹

Clients with moderate or severe anxiety who report improvement in symptoms after two sessions (1+ points on GAD-7)

of clients report improvement in anxiety symptoms ¹

Important FDA Safety Information

Ketamine is not FDA-approved for the treatment of depression or anxiety. Learn more about off-label uses here.

Side effects of ketamine treatment may include: altered sense of time, anxiety, blurred vision, diminished ability to see/hear/feel, dry mouth, elevated blood pressure or heart rate, elevated intraocular or intracranial pressure, excitability, loss of appetite, mental confusion, nausea/vomiting, nystagmus (rapid eye movements), restlessness, slurred speech, synesthesia (a mingling of the senses).

Do not proceed with ketamine treatment if any of the following apply to you:

  • Allergic to ketamine
  • Symptoms of psychosis or mania
  • Uncontrolled high blood pressure
  • CHF or other serious heart problem
  • Severe breathing problem
  • History of elevated intraocular or intracranial pressure
  • History of hyperthyroidism
  • Other serious medical illness
  • Pregnant, nursing, or trying to become pregnant

Ketamine has been reported to produce issues including, but not limited to, those listed below. However, lasting adverse side-effects are rare when medical protocols are carefully followed.

While ketamine has not been shown to be physically addictive, it has been shown to cause moderate psychological dependency in some recreational users.

  • In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
  • Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders.
  • Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your MindBloom® clinician before proceeding with treatment.
  • The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents.

To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:

  • Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
  • Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
  • Continue to take antihypertensive medication as prescribed
  • Avoid hangovers or alcohol intake
  • Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
  • Ketamine treatment should never be conducted without a monitor present to ensure your safety
Read Important Safety Information
Over 74%

of clients with moderate or severe depression or anxiety report significant improvement in their symptoms after four sessions.

Studies have found ketamine to be more effective than traditional medicines for depression.

Research shows that ketamine therapy has a better response rate and shorter time to onset than traditional psychiatric medicine treatments. ²

Traditional medicine

Conventional antidepressant treatment using monoaminergic antidepressants

response rate to conventional antidepressant treatment

and a lag time of weeks to months before onset of clinical effects. ²

Traditional ketamine treatment

Ketamine treatment using intravenous (IV) ketamine administration

response rate to ketamine treatment

and a significant antidepressant response that occurs within 24 hours. ²

Mindbloom® treatment

Clients with moderate or severe depression or anxiety who report significant improvement in symptoms after four sessions (5+ points on PHQ-9 or GAD-7)

response rate to ketamine treatment ¹

Our care team shepherds clients through a safe, impactful experience.

Our experience Clinical and Guide teams spend significant time with clients when compared to traditional psychiatric care. Below are the average touchpoints for clients in the first two months.


Clinician calls


Guide consultations


Mindbloom® sessions


Group sessions

Mindbloom’s treatment protocols were developed by leaders in the scientific community.


Leonardo Vando, MD

Board Certified Psychiatrist and Addiction Psychiatrist with over 15 years of experience in treating the full spectrum of psychiatric and addictive disorders


Casey Paleos, MD

Board certified psychiatrist with over a decade of experience working with ketamine and other psychedelic medicines


Vanila Singh, MD MACM

Former Chief Medical Officer of the U.S. Department of Health and Human Services


Benjamin Weinstein, MD

Chair of Psychiatry and Chief of Service at Houston Methodist Hospital


Teddy Akiki, MD

Dr. Teddy Akiki is a foremost research specialist in the neuroscience of ketamine


Cameron Sepah, PhD

Dr. Cameron Sepah is an Assistant Clinical Professor in UCSF Medical School's Department of Psychiatry


Kristin Arden, PMHNP-BC

Board-certified Psychiatric NP with over 15 years of experience working in mental health

Latest Ketamine Studies.

View more resources

Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept

Read more
Psychiatry Research

Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.

Read more
Nature Communications

Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories

Read more


1. Mindbloom® (2021). Outcomes. Internal Mindbloom® report: unpublished.

2. Lener, M. S., Kadriu, B., & Zarate, C. A., Jr (2017). Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs, 77(4), 381–401.

Receive actionable mental health tips and the latest psychedelic news delivered to your inbox.

Thank you! Your submission has been received!
Something went wrong.
About Us